The Effects of the GOLO for Life® Plan and Release Supplement on Weight Management in Overweight and Obese Adults

Overweight Clinical Trial

Official title:

An Open-label Study Evaluating the Effects of the GOLO for Life® Plan and Release Supplement on Weight Management in Overweight and Obese Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05844631
• Other study ID #: 22GLCFG01
• Status: Completed
• Phase: Phase 2
• Start date: April 20, 2023
• Est. completion date: December 23, 2023

Study information

• Verified date: February 2024
• Source: Golo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to investigate the efficacy and safety of the GOLO for Life® Plan (G4LP) and Release supplementation on weight loss, body composition, and cardiometabolic parameters in overweight and obese adults. The change from baseline at Days 90 and 180 following the G4LP and supplementation with Release in weight (kg and % of total weight) and fat mass (percent and kg) will be assessed by Dual X-Ray Absorptiometry (DEXA). The weekly change in weight (kilograms and percent change) will also be assessed from baseline to day 180 following the G4LP and Release supplementation. Additionally, the safety and tolerability of the G4LP and Release supplementation will be measured by the occurrence of and/or changes in pre-emergent and post-emergent adverse events (AEs).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. completion date: December 23, 2023
• Est. primary completion date: December 23, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Males and females between the age of 18-65 years, inclusive, at screening

2. BMI between 25 and 39.9 kg/m2

3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening

Or,

Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months prior to enrollment. Acceptable methods of birth control include:

• Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)

• Double-barrier method

• Intrauterine devices

• Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)

• Vasectomy of partner at least 6 months prior to screening

• Abstinence and agrees to use contraception if planning on becoming sexually active

4. Self-reported stable body weight defined as not having gained or lost more than 5 kg of body weight in the three months prior to baseline

5. Motivated and ability to comply with G4LP guidelines as assessed by a Self-Motivation Questionnaire at screening (see Appendix 16.2)

6. Agrees to maintain current lifestyle habits as much as possible throughout the study depending on ability to maintain the following: medications, supplements (unless excluded), and sleep

7. Willingness and ability to complete questionnaires, records, and diaries associated with the study, adhere to dietary and exercise guidelines, and to complete all clinic visits

8. Provided voluntary, written, informed consent to participate in the study

Exclusion Criteria:

1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study

2. Allergy, sensitivity, or intolerance to the investigational product ingredients

3. Gastric bypass surgery or other surgeries to induce weight loss

4. Metal implants or other physical characteristics/limitations that may affect DEXA scan results, as assessed by the QI

5. Current participation within the last three months in any weight loss or diet programs

6. Current or history of eating disorders, as assessed by the QI

7. Obesity-induced by metabolic or endocrinologic disorders (ex. acromegaly, hypothalamic obesity), as assessed by the QI

8. Current or history of significant diseases of the gastrointestinal tract, as assessed by the QI

9. Chronic inflammatory diseases, as assessed by the QI

10. Type I diabetes

11. Type 2 diabetes if on insulin treatment

12. History of gout and have had a flare up within 12 months, as assessed by the QI

13. Current unstable diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months

14. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI

15. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI

16. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable

17. Current use of any prescribed or over-the counter medications and/or supplements that may affect body weight or metabolism, as assessed by the QI

18. Regular use of tobacco products within 6 months of baseline and during the study period, as assessed by the QI

19. Chronic inhalation and edible use of cannabinoid products (>1 time/month). Occasional users must agree to wash out and abstain during the study period

20. Alcohol intake average of >2 standard drinks per day

21. Alcohol or drug abuse within the last 12 months

22. Clinically significant abnormal laboratory results at screening, as assessed by the QI

23. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit

24. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI

25. Individuals who are unable to give informed consent

26. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

Related Conditions & MeSH terms

• Obese
• Overweight

Intervention

Dietary Supplement:
• Release
One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.

Locations

Country	Name	City	State
Canada	One Retreat Wellness	Lasalle	Ontario
Canada	KGK Science Inc.	London	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Golo	KGK Science Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The incidence of pre-emergent and post-emergent adverse events (AE).		baseline to day 180
Other	Clinically relevant changes in heart rate (HR)) after 180 days.		baseline to day 180
Other	Clinically relevant changes in aspartate aminotransferase (AST) after 180 days.		baseline to day 180
Other	Clinically relevant changes in alanine aminotransferase (ALT) after 180 days.		baseline to day 180
Other	Clinically relevant changes in alkaline phosphatase (ALP) after 180 days.		baseline to day 180
Other	Clinically relevant changes in total bilirubin after 180 days.		baseline to day 180
Other	Clinically relevant changes in creatinine after 180 days.		baseline to day 180
Other	Clinically relevant changes in electrolytes after 180 days.	Electrolytes to be measured include sodium, potassium, and chloride.	baseline to day 180
Other	Clinically relevant changes in estimated glomerular filtration rate (eGFR) after 180 days.		baseline to day 180
Other	Clinically relevant changes in white blood cell (WBC) count with differential after 180 days.	White blood cells to be measured include neutrophils, lymphocytes, monocytes, eosinophils, and basophils.	baseline to day 180
Other	Clinically relevant changes in red blood cell (RBC) count after 180 days.		baseline to day 180
Other	Clinically relevant changes in hemoglobin after 180 days.		baseline to day 180
Other	Clinically relevant changes in hematocrit after 180 days.		baseline to day 180
Other	Clinically relevant changes in platelet count after 180 days.		baseline to day 180
Other	Clinically relevant changes in immature granulocytes after 180 days.		baseline to day 180
Other	Clinically relevant changes in nucleated red blood cells (RBC) after 180 days.		baseline to day 180
Other	Clinically relevant changes in red blood cell (RBC) mean corpuscular volume (MCV) after 180 days.		baseline to day 180
Other	Clinically relevant changes in mean corpuscular hemoglobin (MCH) after 180 days.		baseline to day 180
Other	Clinically relevant changes in mean corpuscular hemoglobin concentration (MCHC) after 180 days.		baseline to day 180
Other	Clinically relevant changes in red blood cell distribution width (RDW) after 180 days.		baseline to day 180
Primary	The change in weight (kilograms) following the GOLO for Life® Plan (G4LP) and supplementation with Release.	Change in weight will be assessed by Dual X-Ray Absorptiometry (DEXA).	baseline, day 90, day 180
Primary	The change in weight (percentage of total weight) following the GOLO for Life® Plan (G4LP) and supplementation with Release.	Change in weight will be assessed by Dual X-Ray Absorptiometry (DEXA).	baseline, day 90, day 180
Primary	The change in fat mass (percent) following the GOLO for Life® Plan (G4LP) and supplementation with Release.	Change in fat mass will be assessed by Dual X-Ray Absorptiometry (DEXA).	baseline, day 90, day 180
Primary	The change in fat mass (kilograms) following the GOLO for Life® Plan (G4LP) and supplementation with Release.	Change in fat mass will be assessed by Dual X-Ray Absorptiometry (DEXA).	baseline, day 90, day 180
Secondary	The change in body mass index (BMI) from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in muscle mass (percent) as assessed by DEXA from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in android fat (percent) as assessed by DEXA from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in gynoid fat (percent) as assessed by DEXA from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in android/gynoid fat ratio as assessed by DEXA from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in sagittal abdominal diameter (SAD) from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in waist circumference from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in hip circumference from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in arm circumference from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in thigh circumference from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in waist-to-hip ratio from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in lipid levels from baseline at Days 90 and 180 following the G4LP and supplementation with Release.	Lipid levels will be assessed by triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, low-density lipoprotein cholesterol (LDL-C), TC:HDL-C, TG:HDL-C, and LDL-C:HDL-C ratios	baseline, day 90, day 180
Secondary	The change in glycemic control as assessed by HbA1c from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in glycemic control as assessed by serum insulin from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in glycemic control as assessed by serum glucose from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in glycemic control as assessed by HOMA-IR from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in blood pressure from baseline at Days 90 and 180 following the G4LP and supplementation with Release.		baseline, day 90, day 180
Secondary	The change in gastrointestinal symptoms from baseline at Days 90 and 180 following the G4LP and supplementation with Release.	Gastrointestinal symptoms will be assessed by the Modified Gastrointestinal Symptoms Rating Scale (GSRS)	baseline, day 90, day 180
Secondary	The change in subjective sleep efficiency, sleep debt, and sleep difficulty from baseline at Days 90 and 180 following the G4LP and supplementation with Release.	Changes in sleep will be assessed by the Healthy People Sleep Quality Index (HPSQI).	baseline, day 90, day 180
Secondary	The change in stress levels from baseline at Days 90 and 180 following the G4LP and supplementation with Release.	Stress levels will be assessed by the Perceived Stress Scale (PSS) and salivary cortisol.	baseline, day 90, day 180
Secondary	The change in physical activity from baseline at Days 90 and 180 following the G4LP and supplementation with Release.	Physical activity will be assessed by the International Physical Activity Questionnaire (IPAQ).	baseline, day 90, day 180
Secondary	The weekly change in weight (kilogram) from baseline at Day 180 following the G4LP and supplementation with Release.		baseline to day 180
Secondary	The weekly change in weight (percentage) from baseline at Day 180 following the G4LP and supplementation with Release.		baseline to day 180